|
목적 : To report the short-term effects of intravitreal low-dose bevacizumab combined with low-dose triamcinolone injection compared with intravitreal dexamethasone implant (Ozurdex) injection in patients with central retinal vein occlusion
방법 : In total, 46 eyes of 46 patients diagnosed with central retinal vein occlusion were evaluated. Of these, 23 eyes of 23 patients (IVD group) were injected with intravitreal dexamethasone implant, and 23 eyes of 23 patients (Combined group) were injected with low-dose bevacizumab (0.625 mg/0.025 mL) combined with low-dose triamcinolone (1 mg/0.025 mL). The best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) of treated eyes were measured before injection and at 1 month, 2 months, and 3 months after injection
결과 : Groups were similar in age and gender distribution. After the first month, both groups showed significant reduction in CMT (combined group 304.2 ± 67.8 vs. IVD group 324.9 ± 107.6). However, CMT increased during the 3month follow up in the combined group. In the both groups, the BCVA increased significantly at 1 month, 2 months, and 3 months after injection (p< 0.05). Final visual outcome was comparable between IVD group (0.81 ± 0.22 logMAR units) and combined group (0.83 ± 0.38 logMAR units). The IOP showed no significant change at 3 months after injection (p > 0.05) in both groups.
결론 : There were no significant differences in the functional outcomes between the two groups: however, IVD groups showed better anatomical outcomes at 3month. The combined intravitreal injection of low dose bevacizumab and low dose triamcinolone may be a useful alternative treatment option for macular edema associated with central retinal vein occlusion compared with intravitreal dexamethasone implant
|